Altimmune (NASDAQ:ALT) executives highlighted recent clinical and regulatory milestones for pemvidutide and outlined plans to ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lil | Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s Zepbound in a phase 3 weight loss study, further denting the Danish ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 best stocks to invest in during a recession. On February 27, 2026, Amgen Inc. (NASDAQ:AMGN)’s Phase 3 study (NCT05907122) saw an update. The study ...

Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with CNBC, the agency confirmed ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of alternative endpoints in phase 3 oncology trials ...